In Friday’s Wall Street session, Kronos Bio Inc. (NASDAQ:KRON) shares traded at $2.55, down -0.39% from the previous session.
6 analysts cover Kronos Bio Inc. (NASDAQ:KRON), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $36.00 and a low of $7.00, we find $14.00. Given the previous closing price of $2.56, this indicates a potential upside of 446.88 percent. KRON stock price is now -25.44% away from the 50-day moving average and -48.37% away from the 200-day moving average. The market capitalization of the company currently stands at $145.71M.
The stock has received a hold rating from 0 analysts and a buy rating from 6. Brokers who have rated the stock have averaged $16.60 as their price target over the next twelve months.
With the price target of $12, Berenberg recently initiated with Buy rating for Kronos Bio Inc. (NASDAQ: KRON)., while ‘H.C. Wainwright’ rates the stock as ‘Buy’.
In other news, BISCHOFBERGER NORBERT W, President & CEO bought 300,000 shares of the company’s stock on May 19. The stock was bought for $1,134,510 at an average price of $3.78. Upon completion of the transaction, the President & CEO now directly owns 809,609 shares in the company, valued at $2.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 18, President & CEO BISCHOFBERGER NORBERT W bought 206,198 shares of the business’s stock. A total of $768,046 was incurred on buying the stock at an average price of $3.72. This leaves the insider owning 509,609 shares of the company worth $1.3 million. Insiders disposed of 238,788 shares of company stock worth roughly $0.61 million over the past 1 year. A total of 4.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in KRON stock. A new stake in Kronos Bio Inc. shares was purchased by D. E. SHAW & CO., INC. during the first quarter worth $734,000. FEDERATED HERMES, INC. invested $728,000 in shares of KRON during the first quarter. In the first quarter, OASIS MANAGEMENT CO LTD. acquired a new stake in Kronos Bio Inc. valued at approximately $500,000. NEWTYN MANAGEMENT, LLC acquired a new stake in KRON for approximately $323,000. GRAHAM CAPITAL MANAGEMENT, L.P. purchased a new stake in KRON valued at around $234,000 in the second quarter. In total, there are 150 active investors with 63.20% ownership of the company’s stock.
On Friday morning Kronos Bio Inc. (NASDAQ: KRON) stock kicked off with the opening price of $2.5600. During the past 12 months, Kronos Bio Inc. has had a low of $2.28 and a high of $17.49. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 13.20, and a quick ratio of 13.20. The fifty day moving average price for KRON is $3.3866 and a two-hundred day moving average price translates $4.9056 for the stock.
The latest earnings results from Kronos Bio Inc. (NASDAQ: KRON) was released for Jun, 2022.
Kronos Bio Inc.(KRON) Company Profile
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company’s product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.